Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting

Back to Jobs

SAN DIEGO , Sept. 27, 2021 (GLOBE NEWSWIRE) — Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-413 Phase 1/2 trial at

Apply Now